Market Place
Sourcing Support
NJ biopharmas make pledge to give time off for clinical trials
20 Nov 2024 //
FIERCE BIOTECH
Amicus Therapeutics Announces Q3 2024 Financial Results & Updates
06 Nov 2024 //
GLOBENEWSWIRE
Amicus Therapeutics to Present at November Investor Conferences
01 Nov 2024 //
GLOBENEWSWIRE
Amicus Therapeutics to Announce Q3 2024 Results on November 6
28 Oct 2024 //
GLOBENEWSWIRE
Amicus Settles Galafold® Patent Litigation With Teva
17 Oct 2024 //
GLOBENEWSWIRE
Amicus Therapeutics Announces Participation At Muscle Congress
04 Oct 2024 //
GLOBENEWSWIRE
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
03 Sep 2024 //
GLOBENEWSWIRE
Amicus Therapeutics to Present at September 2024 Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Amicus Therapeutics to Present at September Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Amicus Therapeutics To Present At September Investor Conferences
30 Aug 2024 //
GLOBENEWSWIRE
Amicus Therapeutics Announces Q2 2024 Results And Corporate Updates
08 Aug 2024 //
GLOBENEWSWIRE
Amicus Therapeutics To Announce Q2 2024 Results On August 8
30 Jul 2024 //
GLOBENEWSWIRE
Amicus: Presenting At Goldman Sachs Global Healthcare Conference
05 Jun 2024 //
GLOBENEWSWIRE
Amicus: UK Prix Galien For Pombiliti+Opfolda As Best Pharma Product
04 Jun 2024 //
GLOBENEWSWIRE
Amicus Therapeutics Q1 2024 Financials And Updates
09 May 2024 //
GLOBENEWSWIRE
BIO CEO defends the organization`s about-face on the Biosecure Act
09 May 2024 //
ENDPTS
Amicus At BofA 2024 Healthcare Conference
08 May 2024 //
GLOBENEWSWIRE
Amicus Therapeutics Q1 2024 Results On May 9
01 May 2024 //
GLOBENEWSWIRE
Amicus Therapeutics Issues 2024 Envi Social, and Governance (ESG) Report
20 Mar 2024 //
GLOBENEWSWIRE
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
01 Mar 2024 //
GLOBENEWSWIRE
Amicus Announces Full-Year 2023 Financial Results and Corporate Updates
28 Feb 2024 //
GLOBENEWSWIRE
Amicus to Announce Full Year 2023 Financial Results on February 28, 2024
15 Feb 2024 //
GLOBENEWSWIRE
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti
08 Feb 2024 //
GLOBENEWSWIRE
Amicus Announces Presentations and Posters at the 20th Annual WORLDSymposium
01 Feb 2024 //
GLOBENEWSWIRE
Amicus briefs fly in as IRA `fair price` deadline looms
16 Jan 2024 //
ENDPTS
Amicus Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
07 Jan 2024 //
GLOBENEWSWIRE
Amicus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Amicus Congratulates John F. Crowley on Appointment as President and CEO
05 Dec 2023 //
GLOBENEWSWIRE
Amicus Announces Third Quarter 2023 Financial Results and Corporate Updates
08 Nov 2023 //
GLOBENEWSWIRE
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
01 Nov 2023 //
GLOBENEWSWIRE
Amicus to Announce Third Quarter 2023 Financial Results on November 8, 2023
27 Oct 2023 //
GLOBENEWSWIRE
Amicus Announces Presentation and Posters at World Muscle Society 2023
03 Oct 2023 //
GLOBENEWSWIRE
Amicus scores $430M financing deal with asset manager Blackstone
03 Oct 2023 //
FIERCE PHARMA
Amicus` muscle disorder therapy gets FDA nod but restricted label drags shares
29 Sep 2023 //
REUTERS
Orsini Specialty Pharmacy Partners with Amicus Therapeutics
28 Sep 2023 //
PR NEWSWIRE
Amicus Therapeutics to Present at Investor Conferences in September 2023
01 Sep 2023 //
GLOBENEWSWIRE
Amicus Announces Presentation and Posters at the SSIEM Annual Symposium 2023
29 Aug 2023 //
GLOBENEWSWIRE
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
21 Aug 2023 //
GLOBENEWSWIRE
Amicus Announces Approval and Launch of New Pompe Disease Therapy in UK
16 Aug 2023 //
BENZINGA
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy
15 Aug 2023 //
GLOBENEWSWIRE
Amicus Therapeutics Announces Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Amicus to Announce Second Quarter 2023 Financial Results on August 8, 2023
31 Jul 2023 //
GLOBENEWSWIRE
Amicus Therapeutics` Opfolda (miglustat) Receives Approval in Europe
07 Jul 2023 //
EMA
Amicus Therapeutics Announces 1Q 2023 Financial Results and Corporate Updates
10 May 2023 //
GLOBENEWSWIRE
Amicus Therapeutics to Present at Bank of America 2023 Health Care Conference
02 May 2023 //
GLOBENEWSWIRE
Amicus Therapeutics to Announce First Quarter 2023 Financial Results
01 May 2023 //
GLOBENEWSWIRE
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda (miglustat)
26 Apr 2023 //
GLOBENEWSWIRE
WuXi Congratulates Amicus on ECA for Pombiliti
28 Mar 2023 //
PRESS RELEASE
Amicus Announces European Commission Approval for Pombiliti
27 Mar 2023 //
GLOBENEWSWIRE
Amicus Therapeutics Announces Full-Year 2022 Financial Results
01 Mar 2023 //
GLOBENEWSWIRE
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
27 Feb 2023 //
GLOBENEWSWIRE
Amicus Announces Positive Data from PIII Open-label Extension Study of AT-GAA
22 Feb 2023 //
GLOBENEWSWIRE
Amicus to Announce Full-Year 2022 Financial Results on March 1, 2023
14 Feb 2023 //
GLOBENEWSWIRE
Amicus Announces Presentations and Posters at Annual WORLDSymposiumâ„¢ 2023
13 Feb 2023 //
GLOBENEWSWIRE
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
08 Feb 2023 //
GLOBENEWSWIRE
Amicus Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
09 Jan 2023 //
GLOBENEWSWIRE
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
GLOBENEWSWIRE
Amicus’ Therapy Gets Positive CHMP Opinion To Treat Pompe Disease
17 Dec 2022 //
NASDAQ
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
15 Nov 2022 //
GLOBENEWSWIRE
